title: Metabolic activity and mRNA levels of human cardiac CYP450s involved in drug metabolism.
abstract: BACKGROUND
  Tissue-specific expression of CYP450s can regulate the intracellular concentration of drugs and explain inter-subject variability in drug action. The overall objective of our study was to determine in a large cohort of samples, mRNA levels and CYP450 activity expressed in the human heart.
  
  
  METHODS
  CYP450 mRNA levels were determined by RTPCR in left ventricular samples (n = 68) of explanted hearts from patients with end-stage heart failure. Samples were obtained from ischemic and non-ischemic hearts. In some instances (n = 7), samples were available from both the left and right ventricles. A technique for the preparation of microsomes from human heart tissue was developed and CYP450-dependent activity was determined using verapamil enantiomers as probe-drug substrates.
  
  
  RESULTS
  Our results show that CYP2J2 mRNA was the most abundant isoform in all human heart left ventricular samples tested. Other CYP450 mRNAs of importance were CYP4A11, CYP2E1, CYP1A1 and CYP2C8 mRNAs while CYP2B6 and CYP2C9 mRNAs were present at low levels in only some of the hearts analyzed. CYP450 mRNAs did not differ between ischemic and non-ischemic hearts and appeared to be present at similar levels in the left and right ventricles. Incubation of verapamil with heart microsomes led to the formation of nine CYP450-dependent metabolites: a major finding was the observation that stereoselectivity was reversed compared to human liver microsomes, in which the R-enantiomer is metabolized to a greater extent.
  
  
  CONCLUSIONS
  This study determined cardiac mRNA levels of various CYP450 isozymes involved in drug metabolism and demonstrated the prevalent expression of CYP2J2 mRNA. It revealed that cardiomyocytes can efficiently metabolize drugs and that cardiac CYP450s are highly relevant with regard to clearance of drugs in the heart. Our results support the claim that drug metabolism in the vicinity of a drug effector site can modulate drug effects.
authors.affiliation: Research Centre of the University of Montreal Hospital Centre (CRCHUM), Centre Hospitalier de l'Université de Montréal and Faculty of Pharmacy, Université de Montréal, Montreal, Quebec, Canada.
authors.forename: Veronique
authors.initials: V
authors.lastname: Michaud
authors.forename: Martin
authors.initials: M
authors.lastname: Frappier
authors.forename: Marie-Christine
authors.initials: MC
authors.lastname: Dumas
authors.forename: Jacques
authors.initials: J
authors.lastname: Turgeon
mesh_terms: D000889:Anti-Arrhythmia Agents / Q000494:pharmacology; D002851:Chromatography, High Pressure Liquid / Q000379:methods; D003577:Cytochrome P-450 Enzyme System / Q000378:metabolism*; D005260:Female; D006352:Heart Ventricles / Q000187:drug effects; D006801:Humans; D007527:Isoenzymes; D008297:Male; D008862:Microsomes, Liver / Q000378:metabolism; D012333:RNA, Messenger / Q000378:metabolism*; D020133:Reverse Transcriptase Polymerase Chain Reaction; D013237:Stereoisomerism; D014700:Verapamil / Q000494:pharmacology*
chemical_list: D000889:Anti-Arrhythmia Agents; D007527:Isoenzymes; D012333:RNA, Messenger; C400322:cytochrome P-450 CYP2C subfamily; D003577:Cytochrome P-450 Enzyme System; D014700:Verapamil